FDA Accepts NDA for HAISCO's New Drug Application 220482
The FDA has accepted the New Drug Application (NDA) 220482 from HAISCO Pharmaceutical Group Co Ltd for review.
Company
Pharmaceutical intelligence for HAISCO Pharmaceutical Group Co Ltd with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.